CLS Presents Image-Guided Laser, Heat-Induced Cancer Immunotherapy for Tumors at French Medical Laser Society Conference
Lund, Sweden – 24 January, 2020 - Clinical Laserthermia Systems AB (publ) (CLS) today announced its Chief Technology Officer Stephan Dymling will present the company’s Immunostimulating Interstitial Laser Thermotherapy at the French Medical Laser Society Conference this 23-27 January, 2020 in Bourg-Saint-Maurice, France.
The CLS developed imILT® heat-induced cancer immunotherapy for tumors utilizes the TRANBERG® Thermal Therapy System for image-guided, high-precision laser ablation in soft tissues. This enables minimally invasive treatments of tumours and soft tissues using MR or CT/US-guided procedures.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ),develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Germany and USA, is listed Nasdaq First North Growth Market under the ticker CLS B. Certified Adviser: Certified adviser (CA) isFNCA Sweden AB, Ph: +46 8 528 00 399. E-mail: info@fnca.se. Further information is available on www.clinicallaser.se